JANX

In April 2026, Janux Therapeutics announced the discontinuation of clinical development for JANX008. In January 2026, Janux shares rose following a solid tumor license agreement with Bristol Myers Squibb. The company reported its first-quarter financial results in May 2026 and second-quarter financial results in August 2026, with Q2 2026 earnings and revenue reportedly lagging expectations. In September 2026, Janux Therapeutics announced the first patient had been dosed in the Phase 1 clinical trial evaluating JANX013. Over the past three months, Janux stock climbed 19.1% due to pipeline progress, upcoming catalysts, and a strong cash position, though it decreased by 28.86% over the last year and showed a -24.07% decrease, including a significant daily move of -53.3% in December 2025.